Korean J Gastrointest Endosc.  2009 May;38(5):288-293.

Endoscopic Submucosal Dissection of Early Gastric Cancer That Occurred in a Patient with Chronic Myelogenous Leukemia

• Hwangbo Y
• Jang JY
• Shim J
• Dong SH
• Kim HJ
• Kim BH
• Chang YW
• Chang R

Abstract

Synchronous double malignancies of early gastric cancer and chronic myelogenous leukemia (CML) are very rare. There are few reports regarding the effect of the CML or imatinib on stomach cancer, and it is difficult to make a decision for the proper timing of treatment for early gastric cancer (EGC) in a patient with CML. A 56-year-old man was diagnosed with early gastric cancer. During the evaluation of his disease, he was also diagnosed as having Philadelphia chromosome positive chronic myleogenous leukemia. He started to take 400 mg of imatinib per day. Two weeks later, he underwent endoscopic submucosal dissection (ESD) for the early gastric cancer. Although there was a bleeding complication, complete resection was successfully performed. ESD is an effective treatment modality for EGC in CML patients, but physicians should keep a watchful eye for bleeding complications after the procedure. Further studies and more experience are needed to determine the proper timing of treatment for these patients.

Keyword

Gastric cancer; Chronic myelogenous leukemia; Multiple primary cancer; Endoscopic submucosal dissection; Imatinib

MeSH Terms

Benzamides
Eye
Hemorrhage
Humans
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Middle Aged
Philadelphia Chromosome
Piperazines
Pyrimidines
Stomach Neoplasms
Imatinib Mesylate
Benzamides
Piperazines
Pyrimidines